seems this was in the works for a couple of months and this lines up with the quick appointment of the new COO.
I think Jen was pushed as Hopper/(Australian Investors) wanted an Australian based mangement team.
All the trials are US based as well as big pharma so doesn't really seem like the most logical thing to do. Maybe being Aussie based will facilitate face to face roadshows as we are ASX listed after all and funding will likely need to come from Australian based investors and the team at Bell Potter.
Perhaps this will allow CHM to entertain local clinical trials which could be a tough task seeing assests have so far been developed by US Universities.
Maybe as trials progress we can have Phase 1b or Phase 2 trials done locally and alongside US trials.
One could hope for some positives like grant funding, investigator initiated (funded) or better R&D incentives for any local trials.
The fact that the recently hired Trial Co-ordinator is US based makes the above difficult to reconcile.
I am having a harder time trying to read between lines with the company communication (and there is not much) as there doesn't appear to be a consisntent approach or guiding principle behind the decisions.
CHM Price at posting:
2.3¢ Sentiment: None Disclosure: Held
